Phathom's VOQUEZNA Posts 104% Revenue Growth Ahead of DDW 2026 Showcase

Phathom Pharmaceuticals is capitalizing on strong momentum for its flagship acid reflux treatment VOQUEZNA (vonoprazan), reporting explosive revenue growth and planning a significant presence at the upcoming Digestive Disease Week (DDW) 2026 Annual Meeting. The company's first-quarter 2026 net revenues reached $58.3 million, representing a striking 104% year-over-year increase, while the drug has now accumulated 1.35 million total prescriptions filled since launch. The combination of accelerating financial performance and planned clinical presentations signals that Phathom is gaining meaningful market traction in the competitive gastroenterology space.

Key Financial and Clinical Milestones

The company's Q1 2026 results underscore the commercial momentum behind VOQUEZNA, which represents a meaningful breakthrough in acid reflux treatment. Key highlights from the company's performance include:

• $58.3 million in Q1 2026 net revenues, reflecting 104% YoY growth
• 1.35 million total VOQUEZNA prescriptions filled since product launch
• Continued expansion in the gastroesophageal reflux disease (GERD) treatment market
• Planned comprehensive presentation of clinical and real-world evidence at DDW 2026

The doubling of year-over-year revenues demonstrates that VOQUEZNA has moved beyond initial adoption phases and is establishing itself as a meaningful treatment option. The 1.35 million prescription milestone is particularly significant, as it indicates penetration across diverse patient populations and healthcare settings. This scale of prescriptions suggests that physicians are increasingly comfortable with the drug as a first-line or alternative therapy for patients requiring potent acid suppression.

VOQUEZNA's positioning as a first-in-class potassium-competitive acid blocker (P-CAB) offers a novel mechanism of action compared to proton pump inhibitors (PPIs), which have dominated the GERD market for decades. This differentiation appears to be resonating with physicians and patients alike, particularly among those who have experienced inadequate symptom control or side effects with traditional PPI therapy.

Market Context and Competitive Landscape

The timing of Phathom's DDW 2026 presentation arrives as the GERD treatment landscape undergoes significant evolution. The gastrointestinal pharmaceuticals market has long been dominated by established PPI therapies from major manufacturers, but the introduction of novel mechanisms like VOQUEZNA represents a rare instance of meaningful innovation in a therapeutic area often considered mature.

Historically, GERD treatment has been constrained by:

• PPI dependency: Millions of patients rely on chronic proton pump inhibitor therapy, despite long-term safety concerns
• Treatment gaps: A significant patient population experiences inadequate symptom control on standard PPI regimens
• Limited innovation: Few truly novel mechanisms have reached market in recent decades
• Market consolidation: Traditional GERD treatments are primarily marketed by larger pharmaceutical incumbents

The DDW 2026 Annual Meeting is among the largest and most influential gastroenterology conferences globally, attracting thousands of specialists, researchers, and healthcare professionals. For Phathom, this venue represents a critical opportunity to present clinical evidence supporting VOQUEZNA's efficacy and safety profile, reinforcing its differentiation from PPIs and building support among key opinion leaders who influence prescribing patterns.

The presentation of both clinical trial data and real-world evidence is particularly noteworthy. While clinical trials establish efficacy and safety under controlled conditions, real-world data demonstrates how the drug performs when prescribed to diverse patient populations in actual clinical practice—a metric increasingly important to payers, providers, and patients. This dual-data approach strengthens Phathom's value proposition as it seeks to expand market share.

Investor Implications and Forward Momentum

For investors monitoring Phathom Pharmaceuticals, the Q1 2026 results validate the commercial execution thesis that drove initial enthusiasm around VOQUEZNA's launch. The 104% year-over-year revenue growth suggests the drug is not merely capturing niche patient populations but is achieving meaningful adoption across the broader GERD market. At this growth rate, VOQUEZNA is on track to become a significant revenue driver for the company.

The 1.35 million prescription count indicates VOQUEZNA has moved beyond early adopter status. For context, successful specialty pharmaceuticals typically require millions of cumulative prescriptions to meaningfully impact company financials. The fact that Phathom has already achieved this milestone suggests:

• Strong payer acceptance and insurance coverage
• Positive physician sentiment and clinical experience
• Potential for continued market share gains from traditional PPI therapies
• Opportunities for label expansions and additional indications

Looking ahead, the DDW 2026 presentation could serve as a catalyst for further prescription growth if the clinical and real-world data presented reinforce the drug's clinical superiority over PPIs in specific patient populations. Broader adoption could accelerate if healthcare providers and payers embrace VOQUEZNA as a preferred therapy for patients with treatment-resistant GERD or those seeking alternatives to long-term PPI use.

The financial trajectory also has implications for the broader specialty pharmaceutical sector. Phathom's success demonstrates that well-executed innovation in traditionally crowded markets can still generate exceptional growth, provided the drug offers genuine clinical advantages. This may encourage other pharmaceutical companies to pursue novel mechanisms in mature therapeutic categories rather than abandoning them as innovation-resistant spaces.

As Phathom prepares for its DDW 2026 presentations, the company faces an important inflection point. The combination of strong financial performance and planned clinical presentations suggests management confidence in VOQUEZNA's long-term market potential. Investors will be particularly attentive to any data suggesting expanded use cases, improved patient outcomes relative to existing therapies, or evidence supporting premium pricing in the competitive GERD market. The coming months will likely determine whether VOQUEZNA becomes a blockbuster therapy or stabilizes at a more modest market share within the acid reflux treatment space.